EMA Authorised: Vantobra (previously Tobramycin PARI) (tobramycin) — Pari Pharma GmbH

View source ↗

Summary

EMA has authorised Vantobra (tobramycin) for respiratory tract infections including cystic fibrosis, with Pari Pharma GmbH as the marketing authorization holder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Respiratory Tract Infections

Drugs mentioned

• Vantobra

Snippet

Status: Authorised. Therapeutic area: Respiratory Tract Infections;Cystic Fibrosis. MAH: Pari Pharma GmbH. Decision date: 14/10/2023